Developing a personalized immunotherapy for lung cancer patients: Identification of tumor reactive CTLs
Project/Area Number |
16K19990
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Respiratory surgery
|
Research Institution | National Cancer Center Japan |
Principal Investigator |
Yoshikawa Toshiaki 国立研究開発法人国立がん研究センター, 先端医療開発センター, 研究員 (00625957)
|
Project Period (FY) |
2016-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
Keywords | 肺がん / 遺伝子変異由来抗原 / 腫瘍浸潤リンパ球 / 腫瘍免疫学 |
Outline of Final Research Achievements |
The antigens encoded by the tumor-specific somatic mutations are potentially best targets for cancer immunotherapy. To develop a personalized immunotherapy for lung cancer, we characterized the tumor reactive tumor infiltrating lymphocytes (TILs). Surgically resected tumor tissues were obtained from 50 patients with lung cancer. We found the marker to isolate tumor reactive TILs ex vivo. Patient derived xenografts (PDX) were generated from some primary tumor tissues, and, the reactivity of TILs against autologous PDX cancer cells was evaluated. We performed whole-exome sequencing on matched tumor and normal DNA. The candidates of mutated epitopes were identified. We will identify the antigens recognized by these tumor-reactive TILs. Combined with bioinformatics prediction and the assay with ex vivo isolated TILs, we try to determine useful TCR, which recognize antigen for cancer immunotherapy.
|
Report
(3 results)
Research Products
(36 results)
-
-
-
-
[Journal Article] Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma.2017
Author(s)
Ofuji K, Saito K, Suzuki S, Shimomura M, Shirakawa H, Nobuoka D, Sawada Y, Yoshimura M, Tsuchiya N, Takahashi M, Yoshikawa T, Tada Y, Konishi M, Takahashi S, Gotohda N, Nakamoto Y, Nakatsura T.
-
Journal Title
Oncotarget.
Volume: in press
Issue: 23
Pages: 37835-37844
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
[Presentation] Identification and analysis of tumor reactive CTLs in lung cancer tissues for developing a personalized immunotherapy.2017
Author(s)
Yoshikawa T,nosaka K, Suzuki T, Saito K, Shimomura M, Mizuno S, Suzuki Y, Seki M, Sakamoto H, Aoki K, Aokage K, Tsuboi M, Nakatsura T.
Organizer
第36回札幌国際がんシンポジウム
Related Report
Int'l Joint Research
-
[Presentation] Immunological efficacy of glypican-3 (GPC3) peptide vaccine in patients with advanced hepatocellular carcinoma (HCC).2017
Author(s)
Tsuchiya N, Yoshikawa T, Fujinami N, Saito K, Shimomura M, Suzuki T, Nosaka K, Shimizu Y, Akazawa Y, Charneau J, Sawada Y, Endo I, Nakatsura T.
Organizer
第36回札幌国際がんシンポジウム
Related Report
Int'l Joint Research
-
[Presentation] Phase I trial of glypican-3-derived peptide vaccine for refractory pediatric solid tumors.2017
Author(s)
Hosono A, Yoshikawa T, Fujinami N, Saito K, Mizuno S, Tsuchiya N, Hara J, Nitani C, Manabe A, Yoshihara H, Hosoya Y, Kaneda H, Kinoshita Y, Kohashi K, Yoshimura K, Nakatsura T.
Organizer
第36回札幌国際がんシンポジウム
Related Report
Int'l Joint Research
-
-
-
-
[Presentation] Phase 1 study of HSP105‐derived peptide vaccine for patients with advanced esophageal cancer/ colo‐ rectal cancer.2017
Author(s)
Wada S, Kojima T, Nakatsura T, Bando H, Motohashi O, Shimomura M, Yoshikawa T, Kohashi K, Hori A, Ono H, Fukutani M, Wakabayashi M, Nomura S, Sato A, Sasada T, Ohtsu A.
Organizer
The European Society for Medical Oncology(ESMO)
Related Report
Int'l Joint Research
-
-
-
-
[Presentation] Immunological efficacy of glypican-3 (GPC3) peptide vaccine in patients with advanced hepatocellular carcinoma.2017
Author(s)
Tsuchiya N, Yoshikawa T, Fujinami K, Saito K, Shimomura M, Suzuki T, Nosaka K, Shimizu Y, Akazawa Y, Charneau J, Sawada Y, Endo I, Nakatsura T.
Organizer
第76回日本癌学会学術総会
Related Report
-
-
-
-
-
-
-
-
-
[Presentation] In vitroにおけるヒト化抗CD4抗体による末梢血中のCD4陽性細胞除去効果の検討2016
Author(s)
Shimomura M, Kitano S, Syoda K, Iwakami C, Saito Y, Nosaka K, Mizuno S,Yoshikawa T, Yokochi S, Matsushima K, Uemura Y, Nakatsura T.
Organizer
第75回日本癌学会学術総会
Place of Presentation
パシフィコ横浜(神奈川県横浜市)
Year and Date
2016-10-06
Related Report
-
[Presentation] IFNαを産生するiPSC由来増殖性ミエロイド細胞のがん治療への応用2016
Author(s)
Tsuchiya N, Uemura Y, Iwama T, Zhang R, Suzuki T, Yoshikawa T, Sawada Y, Takubo K, Sakaue-Sawano A, Miyawaki A, Endo I, Nakatsura T.
Organizer
第75回日本癌学会学術総会
Place of Presentation
パシフィコ横浜(神奈川県横浜市)
Year and Date
2016-10-06
Related Report
-
-
-
-